The immune-modulating corner of the peptide literature had a busy year, and its headline result was a disappointment. A large randomized trial of Thymosin Alpha-1 in sepsis missed its primary endpoint, while quieter mechanistic and structural work on host-defense peptides kept accumulating. Taken together, the 2025–2026 readouts sketch a field that is mechanistically rich, occasionally reaching definitive human trials, and repeatedly running into the gap between a promising signal and a confirmed effect.
This roundup gathers the notable recent findings on four immune-relevant research peptides in the catalog. It is organized by what was published and when—not by mechanism—so treat each entry as a snapshot of where the evidence stands, not a claim about clinical utility.
Thymosin Alpha-1: a negative phase 3 in sepsis
The most consequential result belongs to Thymosin Alpha-1 (Tα1), a 28-amino-acid peptide derived from the thymic protein prothymosin alpha and long studied as a broad immunomodulator that tunes dendritic-cell signaling and T-cell maturation.
In January 2025, BMJ published TESTS—a multicentre, double-blind, placebo-controlled phase 3 trial testing whether Tα1 reduces mortality in adults with sepsis. It did not. The primary endpoint, 28-day all-cause mortality, was essentially identical between arms (23.4% with Tα1 versus 24.1% with placebo; hazard ratio 0.99). The authors concluded there was no clear evidence that Tα1 decreases 28-day mortality in sepsis. For a compound with two decades of smaller, often encouraging sepsis studies behind it, a well-powered null result is a meaningful correction to the record.
A September 2025 systematic review and meta-analysis in PMC revisited the pooled randomized evidence and reached a similarly cautious overall verdict, but flagged exploratory subgroup signals—improved 28-day survival among septic patients who also had cancer (hazard ratio 0.59) or diabetes. These are hypothesis-generating findings from post-hoc subgroups, not confirmation of benefit, and the review noted the signals were not consistent across higher-quality multicentre studies. The honest reading is that heterogeneity-of-treatment-effect analyses may point future trials toward specific populations, not that Tα1 "works" where the main trial failed.
Separately, immuno-oncology reviews through 2023–2025 have continued to reframe Tα1 as a potential immune-enhancing adjunct, and a phase 2 program (GASTO-1043) has investigated it in radiation pneumonitis during chemoradiotherapy for lung cancer. The through-line: the mechanism remains plausible, but the strongest recent trial was negative.
LL-37: structure and antimicrobial breadth, still no easy clinic path
LL-37 is the only human cathelicidin—a 37-residue amphipathic, alpha-helical peptide cleaved from the hCAP18 precursor and produced by neutrophils, macrophages, and epithelial cells as part of innate defense. It has been studied for direct antimicrobial, antiviral, and immunomodulatory activity.
Two 2025 publications are worth noting. An August 2025 review in the International Journal of Molecular Sciences surveyed the cathelicidin family with a focus on LL-37 and its engineered modifications, cataloguing its remarkably broad in-vitro spectrum across dozens of bacterial, fungal, and viral targets, along with membrane-disruption and biofilm-suppression mechanisms. A November 2025 study in the International Journal of Peptide Research and Therapeutics measured the minimum inhibitory concentrations of recombinantly produced human LL-37 against dozens of clinical bacterial isolates, part of a broader push to make the peptide manufacturable at scale.
The recurring caveat in this literature is translational, not mechanistic: LL-37's low proteolytic stability, concentration-dependent cytotoxicity to host cells, and high production cost keep it largely in the preclinical and derivative-design phase. Much of the 2025 work is aimed at engineered fragments and analogs meant to keep the antimicrobial activity while shedding those liabilities.
VIP: an old sarcoidosis signal, a cautionary COVID chapter
VIP (vasoactive intestinal peptide) is a 28-amino-acid neuropeptide that signals through VPAC1/VPAC2 receptors and has been investigated as an anti-inflammatory and immunoregulatory agent, notably in the lung.
The clearest human signal remains a phase 2 study of inhaled (nebulized) VIP in sarcoidosis, in which four weeks of treatment was well tolerated and was associated with reduced TNF-α production by bronchoalveolar-lavage cells and expansion of regulatory T cells—the first demonstration of a VIP immunoregulatory effect in humans. That result continues to anchor interest in VIP agonists across inflammatory lung disease.
The cautionary counterpoint comes from aviptadil, a synthetic VIP formulation trialed extensively in severe COVID-19, including within the ACTIV-3b/TESICO platform. Despite early enthusiasm, the aviptadil COVID program did not deliver a convincing efficacy result. It is a useful reminder that a compelling mechanism and a positive early-phase readout do not guarantee a positive definitive trial—exactly the pattern the Tα1 sepsis story illustrates.
Ara-290 (cibinetide): a met endpoint, and an orphan-program problem
Ara-290, also called cibinetide, is an 11-amino-acid peptide derived from the tissue-protective domain of erythropoietin. It selectively engages the "innate repair receptor"—a heteromeric complex of the EPO receptor and the beta-common receptor (CD131)—to pursue neuroprotective and anti-inflammatory effects without the red-blood-cell-stimulating activity of EPO itself.
The most mature clinical data sit in sarcoidosis-associated small-fiber neuropathy. A phase 2b randomized, double-blind, placebo-controlled study in patients with painful sarcoid neuropathy met its pre-specified primary endpoint on small-nerve-fiber loss and repair, with supporting signals on neuropathic pain and corneal nerve-fiber density from earlier trials. On the evidence, Ara-290 is one of the better-substantiated compounds in this group.
Its problem is structural, not scientific. Following the closure of the developer, Araim Pharmaceuticals, no sponsor currently holds an active US IND for Ara-290, and as of 2026 there is no phase 3 program or regulatory pathway without a new sponsor. It is a case study in how orphan-indication peptides can stall despite positive mid-stage data—useful context for anyone reading the literature and wondering why a compound with a met endpoint simply went quiet.
What the 2025–2026 readouts have in common
Four peptides, four very different mechanisms—a thymic immunomodulator, a cathelicidin, a neuropeptide, and an EPO-derived tissue-protective peptide. The category label "immune-modulating" hides that diversity, and the recent literature reinforces reading each on its own terms.
A few cross-cutting themes stand out:
- Definitive trials are humbling. Tα1's negative BMJ sepsis result and aviptadil's underwhelming COVID data both followed years of positive-looking smaller studies.
- Subgroup signals are hypotheses, not conclusions. The Tα1 cancer/diabetes subgroups are worth a dedicated trial, not a victory lap.
- Translational barriers dominate. LL-37's stability, toxicity, and cost problems keep the strongest antimicrobial peptide in the human proteome mostly in the lab.
- Good data can strand. Ara-290 shows that a met endpoint does not guarantee a path forward when the sponsor disappears.
For researchers evaluating these compounds, the practical takeaway is to read primary trial readouts and endpoints rather than mechanism summaries, and to weigh sourcing and characterization as carefully as the biology. See our quality standards for how identity and purity are confirmed, and the reference library for compound-level detail.
FAQ
Is Thymosin Alpha-1 the same as Thymalin? No. Both are thymic-derived research peptides, but Thymosin Alpha-1 is a defined 28-amino-acid sequence, while Thymalin is a polypeptide extract fraction. They have distinct research literatures.
Did any of these peptides succeed in a phase 3 trial in 2025? The one large phase 3 covered here—TESTS, testing Thymosin Alpha-1 in sepsis—was negative on its primary endpoint. Ara-290's positive data are from phase 2; VIP's human data are early-phase.
Why do so many of these compounds get studied in sarcoidosis? Sarcoidosis is a granulomatous inflammatory disease with both immune-dysregulation and small-fiber-neuropathy components, making it a natural testing ground for immunomodulatory and tissue-protective peptides like VIP and Ara-290.
This article is educational and for the laboratory research community. Trulogic Labs products are sold for laboratory and research use only and are not for human consumption.